| Autor: |
Rao L; Southern California Institute for Research and Education, VA Long Beach Healthcare System, Long Beach, CA 90822, USA.; Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA., Xu Y; Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA., Reineke LC; Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA., Bhattacharya A; Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA., Tyryshkin A; Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA., Shin JN; Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA., Eissa NT; Southern California Institute for Research and Education, VA Long Beach Healthcare System, Long Beach, CA 90822, USA.; Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA. |
| Abstrakt: |
Alpha one antitrypsin (α1AT), a serine proteinase inhibitor primarily produced by the liver, protects pulmonary tissue from neutrophil elastase digestion. Mutations of the SERPINA1 gene results in a misfolded α1AT protein which aggregates inside hepatocytes causing cellular damage. Therefore, inhibition of mutant α1AT production is one practical strategy to alleviate liver damage. Here we show that proteasome inhibitors can selectively downregulate α1AT expression in human hepatocytes by suppressing the translation of α1AT. Translational suppression of α1AT is mediated by phosphorylation of eukaryotic translation initiation factor 2α and increased association of RNA binding proteins, especially stress granule protein Ras GAP SH3 binding protein (G3BP1), with α1AT mRNA. Treatment of human-induced pluripotent stem cell-derived hepatocytes with a proteasome inhibitor also results in translational inhibition of mutant α1AT in a similar manner. Together we revealed a previously undocumented role of proteasome inhibitors in the regulation of α1AT translation. |
